Clincosm LogoSign in Get a demo

ALDH1A1 Expression in Invasive Mammary Carcinoma

Sponsor
Sohag University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT06134570
Collaborator
(none)
60
Enrollment
1
Location
8
Anticipated Duration (Months)
7.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs.

Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Breast cancer is one of the most common cancers among women. it is a heterogenous disease. several factors affect the prognosis of breast cancer. CSCs markers are one of the emerging prognostic biomarkers.

    ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs.

    Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    ALDH1A1 as A Stem Cell Marker and Its Correlation With the Clinico-pathological Parameters in Invasive Mammary Carcinoma
    Actual Study Start Date :
    Oct 1, 2023
    Anticipated Primary Completion Date :
    Jun 1, 2024
    Anticipated Study Completion Date :
    Jun 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. evaluate expression of ALDH1A1 in invasive mammary carcinoma [4 month]

      immunohistochemical study

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Female
    Inclusion Criteria:
    • Patients with invasive mammary carcinoma carcinoma and underwent surgery
    Exclusion Criteria:

    • Cases received pre-operative chemotherapy or radiotherapy.

    • Cases with insufficient clinical data.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Faculty of Medicine Sohag Egypt

    Sponsors and Collaborators

    • Sohag University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nagwa Abd El-Sadek Ahmed, Lecturer at Pathology Department, Faculty of Medicine, Sohag University
    ClinicalTrials.gov Identifier:
    NCT06134570
    Other Study ID Numbers:
    • Soh-Med-23-09-21PD
    First Posted:
    Nov 18, 2023
    Last Update Posted:
    Nov 18, 2023
    Last Verified:
    Oct 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Nagwa Abd El-Sadek Ahmed, Lecturer at Pathology Department, Faculty of Medicine, Sohag University
    breast cancer
    CSCs
    ALDH1A1
    Additional relevant MeSH terms:
    Breast Neoplasms

    Study Results

    No Results Posted as of Nov 18, 2023